EA202092451A1 - Соединения - Google Patents

Соединения

Info

Publication number
EA202092451A1
EA202092451A1 EA202092451A EA202092451A EA202092451A1 EA 202092451 A1 EA202092451 A1 EA 202092451A1 EA 202092451 A EA202092451 A EA 202092451A EA 202092451 A EA202092451 A EA 202092451A EA 202092451 A1 EA202092451 A1 EA 202092451A1
Authority
EA
Eurasian Patent Office
Prior art keywords
connections
compound
formula
pharmaceutical salt
pharmaceutical
Prior art date
Application number
EA202092451A
Other languages
English (en)
Inventor
Пол Энтони Стаппл
Хелен Рейчел Лагиакос
Бенджамин Джозеф Морроу
Ричард Чарльз Фоитзик
Кэтрин Фей Хемли
Мишель Анг Камерино
Илва Элизабет Бергман Бозикис
Скотт Реймонд Уокер
Original Assignee
СиТиЭксТи ПТИ ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиТиЭксТи ПТИ ЛИМИТЕД filed Critical СиТиЭксТи ПТИ ЛИМИТЕД
Publication of EA202092451A1 publication Critical patent/EA202092451A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединение формулы (I) или его фармацевтическая соль
EA202092451A 2018-06-20 2019-06-20 Соединения EA202092451A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810092.5A GB201810092D0 (en) 2018-06-20 2018-06-20 Compounds
PCT/EP2019/066337 WO2019243491A1 (en) 2018-06-20 2019-06-20 Compounds

Publications (1)

Publication Number Publication Date
EA202092451A1 true EA202092451A1 (ru) 2021-03-16

Family

ID=63042663

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092451A EA202092451A1 (ru) 2018-06-20 2019-06-20 Соединения

Country Status (39)

Country Link
US (2) US20200039945A1 (ru)
EP (2) EP3810602B1 (ru)
JP (1) JP2021529738A (ru)
KR (1) KR20210022655A (ru)
CN (1) CN112334466A (ru)
AR (1) AR114972A1 (ru)
AU (1) AU2019289888A1 (ru)
BR (1) BR112020025869A2 (ru)
CA (1) CA3101238A1 (ru)
CL (1) CL2020003219A1 (ru)
CO (1) CO2020014586A2 (ru)
CR (1) CR20210032A (ru)
CU (1) CU20200096A7 (ru)
DK (1) DK3810602T3 (ru)
DO (1) DOP2020000249A (ru)
EA (1) EA202092451A1 (ru)
EC (1) ECSP20075270A (ru)
ES (1) ES2967983T3 (ru)
FI (1) FI3810602T3 (ru)
GB (1) GB201810092D0 (ru)
GE (1) GEP20227403B (ru)
HR (1) HRP20231467T1 (ru)
HU (1) HUE064744T2 (ru)
IL (1) IL279554A (ru)
LT (1) LT3810602T (ru)
MA (1) MA52948B1 (ru)
MD (1) MD3810602T2 (ru)
MX (1) MX2020012723A (ru)
NI (1) NI202000092A (ru)
PE (1) PE20210181A1 (ru)
PH (1) PH12020500673A1 (ru)
PL (1) PL3810602T3 (ru)
PT (1) PT3810602T (ru)
RS (1) RS64932B1 (ru)
SG (1) SG11202010450VA (ru)
SI (1) SI3810602T1 (ru)
TW (1) TWI826471B (ru)
UY (1) UY38270A (ru)
WO (1) WO2019243491A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471271A1 (en) 2017-10-16 2019-04-17 Acoustical Beauty Improved convolutions of digital signals using a bit requirement optimization of a target digital signal
JP7352662B2 (ja) * 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
JP2022540434A (ja) * 2019-07-12 2022-09-15 キャノピー グロウス コーポレイション カンナビノイド誘導体
BR112023000687A2 (pt) 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
EP4341259A1 (en) * 2021-05-21 2024-03-27 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
EP4368620A1 (en) * 2021-07-05 2024-05-15 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
CA3228411A1 (en) 2021-08-10 2023-02-16 Xiaomin Zhang Sulfonamide derivative, preparation method therefor and medical use thereof
TW202334163A (zh) * 2021-11-16 2023-09-01 香港商英矽智能科技知識產權有限公司 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
US20230303580A1 (en) 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0961780B1 (en) 1997-02-12 2007-04-11 Electrophoretics Limited Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (ru) 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
DK2385938T3 (en) * 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
MX2015010775A (es) * 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
EP3683222B1 (en) * 2014-04-23 2021-10-06 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2018102419A1 (en) * 2016-11-29 2018-06-07 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
JP7352662B2 (ja) * 2019-06-18 2023-09-28 ファイザー・インク ベンゾイソオキサゾールスルホンアミド誘導体

Also Published As

Publication number Publication date
PH12020500673A1 (en) 2021-05-31
AR114972A1 (es) 2020-11-11
TW202016103A (zh) 2020-05-01
DK3810602T3 (da) 2023-12-11
KR20210022655A (ko) 2021-03-03
CO2020014586A2 (es) 2021-03-08
ES2967983T3 (es) 2024-05-06
EP4335439A3 (en) 2024-05-15
US20220153710A1 (en) 2022-05-19
MD3810602T2 (ro) 2024-03-31
TWI826471B (zh) 2023-12-21
ECSP20075270A (es) 2021-02-26
FI3810602T3 (fi) 2023-12-21
HRP20231467T1 (hr) 2024-03-01
HUE064744T2 (hu) 2024-04-28
GEP20227403B (en) 2022-08-10
GB201810092D0 (en) 2018-08-08
CU20200096A7 (es) 2021-08-06
US20200039945A1 (en) 2020-02-06
NI202000092A (es) 2021-03-23
CL2020003219A1 (es) 2021-06-11
BR112020025869A2 (pt) 2021-03-23
PE20210181A1 (es) 2021-01-29
PL3810602T3 (pl) 2024-03-04
CA3101238A1 (en) 2019-12-26
CN112334466A (zh) 2021-02-05
MX2020012723A (es) 2021-05-14
WO2019243491A1 (en) 2019-12-26
LT3810602T (lt) 2024-01-25
MA52948B1 (fr) 2024-02-29
EP3810602B1 (en) 2023-11-01
CR20210032A (es) 2021-02-11
PT3810602T (pt) 2024-01-03
IL279554A (en) 2021-01-31
JP2021529738A (ja) 2021-11-04
DOP2020000249A (es) 2021-02-28
AU2019289888A1 (en) 2020-11-12
UY38270A (es) 2020-01-31
SG11202010450VA (en) 2021-01-28
MA52948A (fr) 2021-04-28
RS64932B1 (sr) 2023-12-29
EP4335439A2 (en) 2024-03-13
SI3810602T1 (sl) 2024-02-29
EP3810602A1 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
EA202092451A1 (ru) Соединения
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
BR112017006253A2 (pt) novos compostos
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201792021A1 (ru) Ингибитор jak
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201592183A1 (ru) Ингибиторы bace
CY1124413T1 (el) Ανταγωνιστες του υποδοχεα cgrp
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
CO2018004213A2 (es) Compuesto piranodipiridínico
EA201491852A1 (ru) Новые пиразольные соединения
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CL2020000376A1 (es) Compuesto pentacíclico.
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
MX2021004386A (es) Compuestos novedosos.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt